Drug Trial Radar · NCT07410117
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,120
Planned (sponsor's estimate)
Start
Mar 9, 2026
Primary completion
Jan 23, 2030
Study completion May 6, 2030
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Feb 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Conditions
- Cancer-Associated Thrombosis (CAT)
Interventions
REGN7508Drug
Administered per the protocol
PlaceboDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related deathTime frame: Through 6 months
- Time-to-first event of centrally adjudicated International Society of Thrombosis and Hemostasis (ISTH) major bleeding or Clinically Relevant Non-Major (CRNM) bleedingTime frame: Through 6 months
Locations
28 sites in 3 countries. Site status is shown where the registry gives one.
Bioresearch Partner- Hialeah Hospital
Hialeah, Florida · Recruiting
Helios Clinical Research
North Miami Beach, Florida · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
El Paso Medical Research Institute (Medresearch Inc)
El Paso, Texas · Withdrawn
American Hospital Tbilisi
Tbilisi, Georgia · Recruiting
Israel Georgia Medical Research Clinic Helsicore
Tbilisi, Georgia · Recruiting
Llc Todua Clinic
Tbilisi, Georgia · Recruiting
Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
Tbilisi, Georgia · Recruiting
Institute of Clinical Oncology
Tbilisi, Georgia · Recruiting
JSC Evex Hospitals - Caraps Medline
Tbilisi, Georgia · Recruiting
LTD Cancer Research Centre
Tbilisi, Georgia · Recruiting
Caucasus Medical Centre
Tbilisi, Georgia · Recruiting
LTD High Technology Hospital Medcenter
Batumi, Adjara, Georgia · Recruiting
Krystyna Kiel Oncology Center
Kutaisi, Imereti, Georgia · Recruiting
Niigata University Medical & Dental Hospital
Niigata, Japan · Recruiting
Ehime University Hospital
Tōon, Ehime, Japan · Recruiting
Gunma Prefectural Cancer Center
Ōta, Gunma, Japan · Recruiting
Hyogo Cancer Center
Akashi, Hyōgo, Japan · Recruiting
Kagawa University Hospital
Kita-gun, Kagawa-ken, Japan · Recruiting
Tokai University Hospital
Isehara-Shi, Kanagawa, Japan · Recruiting
University Hospital Kyoto Prefectural University of Medicine
Kyoto, Kyoto, Japan · Recruiting
Tohoku University Hospital
Sendai, Miyagi, Japan · Recruiting
National Hospital Organization Osaka National Hospital (ONH)
Chuo, Osaka, Japan · Recruiting
Saitama Cancer Center
Ina-machi, Saitama, Japan · Recruiting
National Cancer Center Hospital - Tsukiji Campus
Chuo Ku, Tokyo, Japan · Recruiting
Tokyo Medical University Hospital
Shinjuku, Tokyo, Japan · Recruiting
Yamaguchi University Hospital
Ube, Yamaguchi, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.